Fate Therapeutics, Inc.
FATE
Positions held
Your positionsFATE isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $255.22M | Enterprise value | $177.13M | Trailing P/E | — | Forward P/E | -2.20 |
| PEG | — | Price / book | 1.62 | Beta | 2.53 | Dividend yield | 0.00% |
| Revenue growth | 9.2% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -15.0% |
| Profit margin | 0.0% | ROE | -60.8% | ROA | -26.2% | Debt / equity | 0.49 |
| Current ratio | 4.85 | Free cash flow | -$48.66M | Analyst recommendation | buy | Mean target | $5.74 |
| 52w high | $3.23 | 52w low | $0.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $2.1M | $1.3M | $1.4M | $1.7M | $1.9M |
| Op margin | -1495.4% | -2540.4% | -2536.2% | -1995.1% | -1938.5% |
| Net income | -$30.2M | -$31.2M | -$32.4M | -$32.3M | -$34.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$31.1M | -$33.0M | -$34.7M | -$34.7M | -$37.0M |
- Revenue +60% vs prior quarter ($2.1M vs $1.3M).
- Operating margin expanded to -1495.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | — |
| Op margin | -2222.4% | -1434.5% | -299.9% | -320.2% | — |
| Net income | -$136M | -$186M | -$161M | -$282M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$148M | -$196M | -$191M | -$308M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 · Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
2026-09-25 · Sector Update: Healthcare Stocks Edge Higher Premarket Friday
2026-09-25 · Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial
2026-09-03 · Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
2026-09-02 · Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
2026-08-13 · Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 · Fate Therapeutics: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patterns